Use of nucleolin as a biomarker for lymphangiogenesis in a cancer prognosis and therapy
US10054590B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Aug 8, 2013 |
| Grant date | Aug 21, 2018 |
| Priority date | — |
| Expiry date | Aug 8, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7014
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.